Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance in Indolent and Mantle Cell Lymphomas
NCT00877214Phase 3Active, not recruiting
- Start
- Apr 2009
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Lymphoplasmacytic Lymphoma (LPL), small lymphocytic lymphoma (SLL). Started Apr 2009; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00877214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877214.